Term
|
Definition
| 12 years or older: As adults; 1-2 sprays per nostril BID |
|
|
Term
|
Definition
12 years or older:
As adults; 0.1% or 0.15%: 1-2 sprays per nostril BID,
OR 0.15%: 2 sprays per nostril q Day |
|
|
Term
Astelin 0.1% (125mcg/spray)
Pediatric dose |
|
Definition
<5 years: Safety and efficacy not established
5-11 years: 1 spray per nostril BID |
|
|
Term
Astepro 0.15% (187.6mcg/spray)
Pediatric dose |
|
Definition
| <12 years: Safety and efficacy not established |
|
|
Term
Atrovent Nasal Spray 0.03% and 0.06%
Adult Dose |
|
Definition
Allergic/nonallergic rhinitis: 2 sprays (0.03%) per nostril BID/TID
Rhinitis due to common cold: 2 sprays (0.06%) per nostril TID/QID |
|
|
Term
Atrovent Nasal Spray 0.03% and 0.06%
Pediatric Dose |
|
Definition
<5 years: Safety & efficacy not established
5-12 years: 2 sprays (0.06%) in each nostril TID
>12 years: 2 sprays (0.06%) in each nostril TID/QID |
|
|
Term
|
Definition
<2 years: Safety and efficacy not established
2 years or older: 1 spray each nostril TID-QID, may increase to 6 times/day; may take 2-4 weeks before symptomatic relief observed
For best results, initiate 1-2 weeks before contact with allergens |
|
|
Term
Patanase 6%, 665mcg/spray
Adult dose |
|
Definition
|
|
Term
Patanase 6%, 665mcg/spray
Pediatric dose |
|
Definition
<6 years: Safety and efficacy not established
6-11 years: 1 spray per nostril BID |
|
|
Term
Beconase AQ 42 mcg/spray
Adult dose |
|
Definition
| 1-2 sprays/nostril BID (total dose: 168-336 mcg/day) |
|
|
Term
Beconase AQ 42 mcg/spray
Pediatric dose |
|
Definition
<6 years old: Safety and efficacy not established
6-11 years old: 1 spray/nostril BID (168 mcg/day); may increase to 2 sprays/nostril (336 mcg/day) in patients not adequately responding or those with more severe symptoms; decrease dose to 1 spray/nostril BID once adequate control achieved |
|
|
Term
Omnaris 50mcg/actuation
Adult dose |
|
Definition
|
|
Term
Omnaris 50mcg/actuation
Pediatric dose |
|
Definition
<6 years: Safety and efficacy not established
6 years or older: As adults; 2 sprays/nostril qDay (ie, 200 mcg/day) |
|
|
Term
Flonase, Veramyst (fluticasone)50mcg/spray
Adult dose |
|
Definition
2 sprays in each nostril qDay (ie, 200 mcg/day)
After first few days, patient may reduce dosage to 1 spray in each nostril qDay (ie, 100 mcg/day) |
|
|
Term
Flonase, Veramyst (fluticasone)50mcg/spray
Pediatric dose |
|
Definition
| >4 years: 1 spray (50 mcg) in each nostril qDay; may increase up to 2 sprays/nostril qDay |
|
|
Term
Nasonex 50mcg/spray
Adult dosing |
|
Definition
| 2 sprays (100 mcg) in each nostril qDay |
|
|
Term
Nasonex 50mcg/spray
Pediatric dosing |
|
Definition
<2 years: Safety and efficacy not established
2-11 years: 1 spray (50 mcg) in each nostril qDay |
|
|
Term
Nasacort AQ triamcinolone 55mcg/spray
Adult dosing |
|
Definition
| 220 mcg qDay as 2 sprays/nostril qDay |
|
|
Term
Nasacort AQ triamcinolone 55mcg/spray
Pediatric dosing |
|
Definition
<2 years: Safety and efficacy not established
2-5 years: 110 mcg/day as 1 spray/nostril qDay
6-11 years: 110 mcg/day as 1 spray/nostril qDay; may increase to 2 sprays/nostril qDay (ie, 220 mcg/day) |
|
|
Term
Mucinex
Category and Indication/Dx |
|
Definition
Expectorant/Mucous thinner
DX: Respiratory infections |
|
|
Term
|
Definition
| Extended Release: 1-2 tablets (600-1200 mg) PO q12hr; not to exceed 4 tablets/24 hr (2.4 g/day) |
|
|
Term
Nasacort AQ
Category and Indication/Dx |
|
Definition
Nasal Steroid
Antiinflammatory
DX: Allergic Rhinitis, Vasomotor Rhinitis |
|
|
Term
Nasonex
Category and Indication/Dx |
|
Definition
Nasal Steroid
Antiinflammatory
DX: Allergic Rhinitis, Vasomotor Rhinitis |
|
|
Term
Flonase
Category and Indication/Dx |
|
Definition
Nasal Steroid
Antiinflammatory
DX: Allergic Rhinitis, Vasomotor Rhinitis |
|
|
Term
Veramyst
Category and Indication/Dx |
|
Definition
Nasal Steroid
Antiinflammatory
DX: Allergic Rhinitis, Vasomotor Rhinitis |
|
|
Term
Omnaris
Category and Indication/Dx |
|
Definition
Nasal Steroid
Antiinflammatory
DX: Allergic Rhinitis, Vasomotor Rhinitis |
|
|
Term
Beconase AQ
Category and Indication/Dx |
|
Definition
Nasal Steroid
Antiinflammatory
DX: Allergic Rhinitis, Vasomotor Rhinitis |
|
|
Term
Patanase
Category and Indication/Dx |
|
Definition
Nasal Antihistamine
DX: Allergic Rhinitis, Vasomotor Rhinitis |
|
|
Term
Astelin
Category and Indication/Dx |
|
Definition
Nasal Antihistamine
DX: Allergic Rhinitis, Vasomotor Rhinitis |
|
|
Term
Astepro
Category and Indication/Dx |
|
Definition
Nasal Antihistamine
DX: Allergic Rhinitis, Vasomotor Rhinitis |
|
|
Term
Atrovent
Category and Indication/Dx |
|
Definition
Anticholinergic drying agent
Dx: Vasomotor Rhinitis |
|
|
Term
Mucinex D
Regular Strength: 600mg + 60mg pseudoephedrine
Maximum Strength: 1200mg + 120mg pseud |
|
Definition
| Expectorant/Mucous thinner + decongestant |
|
|
Term
|
Definition
1 maximum strength or 1-2 regular bid .
Do not take after 6 pm to avoid insomnia
Avoid with HTN, arrythmia, insomnia |
|
|
Term
Mucinex DM
Regular Strength: 600mg + 30mg DM
Maximum Strength: 1200mg + 60mg DM |
|
Definition
| Expectorant/Mucous thinner + cough suppressant (DextroMethorphan...DM) |
|
|
Term
|
Definition
| 1 maximum strength or 1-2 regular bid |
|
|
Term
Tessalon Perles
Category and Indication/Dx |
|
Definition
|
|
Term
Tessalon Perles 100 mg or 200 mg
Adult Dosing |
|
Definition
100 mg PO TID; 600 mg/day maximum
Swallow whole; do not chew |
|
|
Term
Tessalon Perles 100 mg or 200 mg
Pediatric Dosing |
|
Definition
<10 years old: Safety & efficacy not established
>10 years old: As in adults
Swallow whole; do not chew |
|
|
Term
|
Definition
Inhaled Corticosteroid
Asthma "Controller" |
|
|
Term
Rhinocort Aqua (budesonide) 32mcg/spray
Category and Indication/Dx |
|
Definition
Nasal Steroid
Antiinflammatory
DX: Allergic Rhinitis, Vasomotor Rhinitis |
|
|
Term
Rhinocort Aqua (budesonide) 32mcg/spray
Adult dosing |
|
Definition
| 1-2 sprays each nostril qday |
|
|
Term
Rhinocort Aqua (budesonide) 32mcg/spray
Pediatric dosing |
|
Definition
< 1 years old: Safety & efficacy not established
1-8 years old: 1 spray each nostril qday |
|
|
Term
Pulmicort Flexihaler 90ug and 180ug
Dosing (> 8 years old) |
|
Definition
1-3 inhalations 1-2x/day
RINSE MOUTH AFTER USE |
|
|
Term
Pulmicort Respules suspension for nebulizer
0.25mg/2mL 0.5mg/2mL 1mg/2mL |
|
Definition
< 1 years old: Safety & efficacy not established
1-8 years old: 0.5 mg qDay or BID; 1 mg/day maximum
RINSE MOUTH AFTER USE |
|
|
Term
Pulmicort Respules (budesonide)
Category and Indication/Dx |
|
Definition
Nebulized inhaled corticosteroid
Asthma "Controller |
|
|
Term
Asmanex Twisthaler
Category and Indication/Dx |
|
Definition
Inhaled corticosteroid
Asthma "Controller |
|
|
Term
Asmanex Twisthaler 110mcg 220mcg
Adult dosing |
|
Definition
Up to 220 mcg inhaled PO 1-2x/day
RINSE MOUTH AFTER USE |
|
|
Term
Asmanex Twisthaler 110mcg 220mcg
Pediatric dosing |
|
Definition
4-11 years old: 110 mcg inhaled PO q Evening; not to exceed 110 mcg/day
12 years or older: Same as adults; 220 mcg inhaled PO qDay |
|
|
Term
Alvesco (ciclesonide)
Category and Indication/Dx |
|
Definition
Inhaled corticosteroid
Asthma "Controller |
|
|
Term
Alvesco (ciclesonide) 80mcg/puff
160mcg/puff
Adult dosing |
|
Definition
80 mcg inhaled BID initially; may increase to 320 mcg BID
RINSE MOUTH AFTER USE
Consider using a spacer |
|
|
Term
Alvesco (ciclesonide) 80mcg/puff
160mcg/puff
Pediatric dosing |
|
Definition
<12 years: Safety and efficacy not established
>12 years or older: As adults |
|
|
Term
Flovent (fluticasone) Diskus or HFA
Category and Indication/Dx |
|
Definition
Inhaled corticosteroid
Asthma "Controller |
|
|
Term
Flovent (fluticasone) HFA (aerosol)
44mcg/inh 110mcg/inh 220mcg/inh
Adult dosing |
|
Definition
88 mcg (2 puffs) inhaled PO BID; may incr to max 880 mcg inhaled PO BID
RINSE MOUTH AFTER USE
Consider using a spacer |
|
|
Term
Flovent (fluticasone) HFA (aerosol)
44mcg/inh 110mcg/inh 220mcg/inh
Pediatric Dosing |
|
Definition
4-11 years: 88 mcg (2 puffs) inhaled PO BID
12 years or older: as adult; initial 88 mcg (2 puffs) inhaled PO BID; may incr to max 440 mcg inhaled PO BID
RINSE MOUTH AFTER USE
Consider using a spacer |
|
|
Term
Flovent (fluticasone) Diskhaler
50mcg/inh 100mcg/inh 250mcg/inh
Adult Dose |
|
Definition
100 mcg inhaled PO BID; may incr to max 1000 mcg BID
RINSE MOUTH AFTER USE |
|
|
Term
Flovent (fluticasone) Diskhaler
50mcg/inh 100mcg/inh 250mcg/inh
Pediatric Dose |
|
Definition
4-11 years: 50-100 mcg inhaled PO BID
12 years or older: same as adult dosing; initial 100 mcg inhaled PO BID; may incr to max 500 mcg BID
RINSE MOUTH AFTER USE |
|
|
Term
Albuterol
Category and Indication/Dx |
|
Definition
Asthma "Relief" inhaled medication
Short acting |
|
|
Term
Albuterol
Brand name inhalers |
|
Definition
| Proventil HFA, Ventolin HFA, Proair HFA, Proventil |
|
|
Term
Albuterol
Brand name nebulizer solutions |
|
Definition
Proventil, Ventolin nebulizer Solution
0.083% premixed ampules
0.5% to mix w saline |
|
|
Term
|
Definition
2 puffs inhaled PO q4-6hr
0.5 mL of 0.5% solution (2.5 mg) or 1 ).083% ampule nebulized q4-8hr PRN |
|
|
Term
Albuterol
Pediatric dosing |
|
Definition
Inhaler: >4 years old: As adult; 1-2 inhalations PO q4-6 hr (Use spacer)
<2 years old (off-label): 0.2-0.6 mg/kg/day divided q4-6hr nebulized
2-12 years old, >15 kg: 0.63-2.5 mg TID/QID |
|
|
Term
Xopenex
Category and Indication/Dx |
|
Definition
Asthma "Relief" inhaled medication
Short acting
Less jittery and tachycardia |
|
|
Term
Xopenex neb solution
0.31mg/3mL 0.63mg/3mL 1.25mg/3mL
1.25mg/5mL
Adult dosing |
|
Definition
| 0.63-1.25 mg neb TID (q6-8hr) |
|
|
Term
Xopenex HFA MDI 45mcg/inh
Adult dosing |
|
Definition
2 inh (90 mcg total) q4-6hr
Consider using a spacer |
|
|
Term
Xopenex HFA MDI 45mcg/inh
Pediatric dosing |
|
Definition
<4 yo: Safety & efficacy not established
>4 yo: 2 puffs q4-6hr PRN
Consider using a spacer |
|
|
Term
Xopenex neb solution
0.31mg/3mL 0.63mg/3mL 1.25mg/3mL
1.25mg/5mL
Pediatric dosing |
|
Definition
< 4 yo: Safety & efficacy not established
> 4yo: 6-12 yo: 0.31 mg neb TID; not to exceed 0.63 mg TID
>12 yo: 0.63-1.25 mg q8hr PRN |
|
|
Term
Foradil
Category and Indication/Dx |
|
Definition
Asthma "Relief" inhaled medication
Long acting (12 hours)
Quick onset |
|
|
Term
Foradil Aerolizer
12mcg/cap
Adult dosing |
|
Definition
Foradil Aerolizer: 12 mcg inhaled q12hr
NEVER MORE THAN TWICE DAILY/q 12 hours |
|
|
Term
Foradil Aerolizer
12mcg/cap
Pediatric dosing |
|
Definition
<5 years: Safety and efficacy not established
5 years or older: As adult (Foradil Aerolizer); 12 mcg inhaled PO q12hr
NEVER MORE THAN TWICE DAILY/q 12 hours |
|
|
Term
Serevent Diskus
Category and Indication/Dx |
|
Definition
Asthma "Relief" inhaled medication
Long acting (12 hours)
Delayed (45-60 minutes) onset |
|
|
Term
Serevent Diskus 50mcg/inhalation
Adult dosing |
|
Definition
1 inhalation (50 mcg) BID
NEVER MORE THAN TWICE DAILY/q 12 hours |
|
|
Term
Serevent Diskus 50mcg/inhalation
Pediatric dosing |
|
Definition
| Children 4 years and older dose same as adult |
|
|
Term
Singulair (montelukast)
Category and Indication/Dx |
|
Definition
Oral anti inflammatory (non steroid)
Asthma "Controller" medication |
|
|
Term
Singulair (montelukast)
Adult dosing |
|
Definition
| 10 mg PO q Evening (use 10 mg tablet) |
|
|
Term
Singulair (montelukast) chewable 4mg,5mg
oral granules 4mg/packet
Pediatric dosing |
|
Definition
<12 months: Safety and efficacy not established
12-24 months: 4 mg (granules) PO qEvening
2-5 years: 4 mg (chewable tablet or granules) PO qEvening
6-14 years: 5 mg (chewable tablet) PO qEvening
15 years or older: 10 mg (conventional tablet) PO qEvening |
|
|
Term
Advair Diskus or HFA
Flovent/serevent)
Category and Indication/Dx |
|
Definition
Combination:
Long Acting relief + Controller (ICS) |
|
|
Term
Advair Diskus
(50mcg/100mcg)/actuation
(50mcg/250mcg)/actuation
(50mcg/500mcg)/actuation
Adult dosing |
|
Definition
nitial dose based on asthma severity
1 inhalation PO BID initially of 50/100 or 50/250
Not to exceed 1 inhalation PO BID of 50/500
NEVER MORE THAN TWICE DAILY/q 12 hours
NEVER USE FOR QUICK RELIEF
RINSE MOUTH AFTER USE |
|
|
Term
Advair Diskus
(50mcg/100mcg)/actuation
(50mcg/250mcg)/actuation
(50mcg/500mcg)/actuation
Pediatric dosing |
|
Definition
<4 years: Safety and effiacy not established
4-11 years: 1 inhalation PO BID of 50/100
12 years or older: As adults; 1 inhalation PO BID initially; dose is based on asthma severity; not to exceed 1 inhalation PO BID of 50/500
NEVER MORE THAN TWICE DAILY/q 12 hours
NEVER USE FOR QUICK RELIEF |
|
|
Term
Advair HFA
(21mcg/45mcg)/actuation
(21mcg/115mcg)/actuation
(21mcg/230mcg)/actuation
Pediatric Dosing |
|
Definition
<12 years: Safety and effiacy not established
Dose is based on asthma severity
12 years or older: As adults; 2 inhalations PO BID; not to exceed 2 inhalations PO BID of 21/230
NEVER MORE THAN TWICE DAILY/q 12 hours
NEVER USE FOR QUICK RELIEF
Consider using a spacer
RINSE MOUTH AFTER USE |
|
|
Term
Advair HFA
(21mcg/45mcg)/actuation
(21mcg/115mcg)/actuation
(21mcg/230mcg)/actuation
Adult Dosing |
|
Definition
nitial dose based on asthma severity
2 inhalations PO BID
Not to exceed 2 inhalations PO BID of 21/230
NEVER MORE THAN TWICE DAILY/q 12 hours
NEVER USE FOR QUICK RELIEF
Consider using a spacer
RINSE MOUTH AFTER USE |
|
|
Term
Symbicort Turbuhaler
(pulmicort/foradil)
Category and Indication/Dx |
|
Definition
Combination:
Long Acting relief + Controller (ICS) |
|
|
Term
Symbicort Turbuhaler
(80mcg/4.5mcg)/puff
(160mcg/4.5mcg)/puff
Adult dosing |
|
Definition
2 inhalations twice daily depending on severity of asthma
NEVER MORE THAN TWICE DAILY/q 12 hours
Consider using a spacer
RINSE MOUTH AFTER USE |
|
|
Term
(80mcg/4.5mcg)/puff
(160mcg/4.5mcg)/puff
Pediatric dosing |
|
Definition
<12 years old: Safety & efficacy not established
>12 years old: As in adults
NEVER MORE THAN TWICE DAILY/q 12 hours
Consider using a spacer
RINSE MOUTH AFTER USE |
|
|
Term
Dulera
Category and Indication/Dx |
|
Definition
Combination:
Long Acting relief + Controller (ICS |
|
|
Term
Dulera MDI 100mcg/5mcg/actuation 200mcg/5mcg/actuation
(mometasone inhaled/formoterol)
Adult dosing |
|
Definition
2 inhalations PO BID
NEVER MORE THAN TWICE DAILY/q 12 hours
Consider using a spacer
RINSE MOUTH AFTER USE |
|
|
Term
Dulera MDI 100mcg/5mcg/actuation 200mcg/5mcg/actuation
(mometasone inhaled/formoterol)
Pediatric dosing |
|
Definition
<12 years: Safety and efficacy not established
12 years or older: As adults; 2 inhalations PO BID |
|
|
Term
Medications indicated for
< age 4 |
|
Definition
Nasalcrom (age 2)
Nasonex (age 2)
Nasacort AQ (age 2)
Rhinocort AQ, Pulmicort neb (age 1)
Singulair granules
Xopenex nebulizer |
|
|
Term
| Medications indicated to age 5 and over |
|
Definition
Astelin,
Atrovent
Foradil
Singulair 5mg (until age 15) |
|
|
Term
| Medications indicated for age 6 and over |
|
Definition
Patanase,
Beconase,
Omnaris |
|
|
Term
| Medications indicated to age 4 and over |
|
Definition
Flonase,
Veramyst
Asmanex
Advair
Xopenex HFA |
|
|
